Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex

Omeima Abdullah (1) , Ziad Omran (1) , Salman Hosawi (2) , Ali Hamiche (3) , Christian Bronner (3) , Mahmoud Alhosin (2)

1 Umm Al-Qura University
2 King Abdulaziz University
3 IGBMC - Institut de Génétique et de Biologie Moléculaire et Cellulaire

Silencing of tumor suppressor genes (TSGs) through epigenetic mechanisms, mainly via abnormal promoter DNA methylation, is considered a main mechanism of tumorigenesis. The abnormal DNA methylation profiles are transmitted from the cancer mother cell to the daughter cells through the involvement of a macromolecular complex in which the ubiquitin-like containing plant homeodomain (PHD), and an interesting new gene (RING) finger domains 1 (UHRF1), play the role of conductor. Indeed, UHRF1 interacts with epigenetic writers, such as DNA methyltransferase 1 (DNMT1), histone methyltransferase G9a, erasers like histone deacetylase 1 (HDAC1), and functions as a hub protein. Thus, targeting UHRF1 and/or its partners is a promising strategy for epigenetic cancer therapy. The natural compound thymoquinone (TQ) exhibits anticancer activities by targeting several cellular signaling pathways, including those involving UHRF1. In this review, we highlight TQ as a potential multitarget single epidrug that functions by targeting the UHRF1/DNMT1/HDAC1/G9a complex. We also speculate on the possibility that TQ might specifically target UHRF1, with subsequent regulatory effects on other partners.

Mots clés: thymoquinone; UHRF1; epigenetic drug; cancer; tumor suppressor gene

Domaines: Cancer; Génomique, Transcriptomique et Protéomique [q-bio.GN]; Pharmacologie

Omeima Abdullah, Ziad Omran, Salman Hosawi, Ali Hamiche, Christian Bronner, et al.. Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex. Genes, 2021, 12 (5), pp.622. ⟨10.3390/genes12050622⟩. ⟨hal-03484319⟩